目的探讨长链非编码RNA(lncRNA)NUTM2B-AS1在口腔鳞状细胞癌组织中的表达及对口腔鳞状细胞癌细胞侵袭和迁移的影响及分子机制。方法采用癌症基因组图谱(The Cancer Genome Atlas,TCGA)数据库分析口腔鳞状细胞癌组织和癌旁组织中NUTM2B-...目的探讨长链非编码RNA(lncRNA)NUTM2B-AS1在口腔鳞状细胞癌组织中的表达及对口腔鳞状细胞癌细胞侵袭和迁移的影响及分子机制。方法采用癌症基因组图谱(The Cancer Genome Atlas,TCGA)数据库分析口腔鳞状细胞癌组织和癌旁组织中NUTM2B-AS1表达水平。qRT-PCR法检测口腔上皮角质细胞HOK、口腔鳞状细胞癌细胞系Cal-27、SCC-25、SCC-9、HSC-3中NUTM2B-AS1表达水平。Cal-27细胞分别转染NUTM2B-AS1过表达载体(pmirGLO-NUTM2B-AS1)和空载体(pmirGLO),记为NUTM2B-AS1组和对照组,qRT-PCR验证每组细胞中NUTM2B-AS1表达水平。Transwell侵袭实验和细胞划痕实验检测Cal-27细胞侵袭和迁移。生物信息学方法和双荧光素酶报告基因实验验证NUTM2B-AS1和miR-770-5p的靶向关系。qRT-PCR检测Cal-27细胞miR-770-5p的表达,Western blot检测Cal-27细胞Sirt7/Smad4信号通路蛋白(Sirt7、E-cadherin、Smad4、MMP-7、Vimentin)的表达。结果与癌旁组织比较,口腔鳞状细胞癌组织中NUTM2B-AS1表达显著降低(P<0.01)。与HOK细胞比较,口腔鳞状细胞癌细胞系Cal-27、SCC-25、SCC-9、HSC-3中NUTM2B-AS1表达显著降低(P<0.01),Cal-27细胞中NUTM2B-AS1表达最低(P<0.01)。与对照组比较,NUTM2B-AS1组Cal-27细胞中NUTM2B-AS1表达显著升高(P<0.01)。与对照组比较,NUTM2B-AS1组Cal-27细胞侵袭数显著降低(P<0.01),Cal-27细胞划痕愈合率显著降低(P<0.01)。miR-770-5p是NUTM2B-AS1的靶向结合基因(P<0.01)。与对照组相比,NUTM2B-AS1组Cal-27细胞中miR-770-5p表达显著降低(P<0.01),Sirt7、E-cadherin蛋白表达显著升高(P<0.01),Smad4、MMP-7、Vimentin蛋白表达下降(P<0.01)。结论NUTM2B-AS1在口腔鳞状细胞癌组织和细胞系中低表达,高表达NUTM2B-AS1可抑制口腔鳞状细胞癌细胞侵袭和迁移,其作用机制与靶向下调miR-770-5p表达有关。展开更多
1.INTRODUCTION NUT midline carcinoma family member 1(NUTM1)fusions are primarily known for their association with poorly differen-tiated and aggressive carcinomas,predominantly affecting mid-line structures in childre...1.INTRODUCTION NUT midline carcinoma family member 1(NUTM1)fusions are primarily known for their association with poorly differen-tiated and aggressive carcinomas,predominantly affecting mid-line structures in children and young adults.Recently,NUTM1 fusions have been identified various malignancies,including hematologic malignancies.1 Among these,NUTM1-rearranged B-cell lymphoblastic leukemia(B-ALL)has emerged as a dis-tinct subtype that typically presents in children and is associated with positive clinical outcomes.展开更多
伴睾丸核蛋白(nuclear protein in testis,NUT)基因重排的中线癌又称NUT癌,是一种罕见的高度侵袭性肿瘤,根据NUT中线癌家族成员1(NUT midline carcinoma family member 1,NUTM1)基因发生重排或突变定义。常规治疗方法对NUT癌效果欠佳,...伴睾丸核蛋白(nuclear protein in testis,NUT)基因重排的中线癌又称NUT癌,是一种罕见的高度侵袭性肿瘤,根据NUT中线癌家族成员1(NUT midline carcinoma family member 1,NUTM1)基因发生重排或突变定义。常规治疗方法对NUT癌效果欠佳,绝大多数患者预后差。现阶段对该基因变异的认识不足是制约NUT癌诊治取得进展的主要障碍。目前在临床实践中缺乏针对NUT癌临床特征、诊断及治疗方法的标准化指南,限制了临床医师对该疾病的充分认识。为了给临床医师提供更加明确规范的诊断参考依据,中国抗癌协会肿瘤基因诊断专业委员会中线(NUT)癌基因诊断工作组及中国抗癌协会肿瘤标志专业委员会组织了临床、病理、分子检测和生物信息分析等领域专家,综合国内外NUT癌临床应用的共识指南、重要文献及临床实践经验,共同制定了本共识,对NUT癌临床诊疗给出专家组意见,期望为临床医师提供NUT癌诊疗指导意见,降低NUT癌误诊率,提高治疗效果和预后。展开更多
中线癌(nuclear protein in testis carcinoma),又称NUT癌,是一种罕见的高度侵袭性恶性肿瘤,最常见于中线器官和肺。NUT癌的特征性遗传学改变是NUT癌家族成员1(NUT midline carcinoma family member 1,NUTM1)基因重排。本文将对其最常...中线癌(nuclear protein in testis carcinoma),又称NUT癌,是一种罕见的高度侵袭性恶性肿瘤,最常见于中线器官和肺。NUT癌的特征性遗传学改变是NUT癌家族成员1(NUT midline carcinoma family member 1,NUTM1)基因重排。本文将对其最常见的融合形式溴结构域蛋白4(bromodomaincontaining protein 4,BRD4)-NUTM1融合基因的致病机制以及靶向药物研发的进展进行综述。展开更多
伴睾丸核蛋白(nuclear protein in testis,NUT)基因重排的中线癌是一种由NUTM1(NUT midline carcinoma family member 1)基因重排定义的罕见高侵袭性肿瘤。常规治疗方法对NUT癌效果欠佳,绝大多数患者预后差。《中线(NUT)癌诊断与治疗专...伴睾丸核蛋白(nuclear protein in testis,NUT)基因重排的中线癌是一种由NUTM1(NUT midline carcinoma family member 1)基因重排定义的罕见高侵袭性肿瘤。常规治疗方法对NUT癌效果欠佳,绝大多数患者预后差。《中线(NUT)癌诊断与治疗专家共识(2023版)》于2023年10月发布,以期为临床医师提供更加明确和规范的诊治参考依据,对广大NUT癌患者有着重要意义。本文将对该共识的主要内容进行解读。展开更多
1(NUTM1)gene rearrangements(15q14).In 1991,two independent research teams reported NC cases characterized by the t(15;19)translo-cation.1,2 In vitro studies by French et al.3 led to the pivotal discovery of NC in 2003...1(NUTM1)gene rearrangements(15q14).In 1991,two independent research teams reported NC cases characterized by the t(15;19)translo-cation.1,2 In vitro studies by French et al.3 led to the pivotal discovery of NC in 2003 as a distinct disease entity driven by the fusion of bromodo-main and extraterminal domain(BET)protein 4(BRD4)and NUTM1.In 2004,the World Health Organization(WHO)classified tumors with t(15;19)translocation as a thymic malignancy and designated it“NUT midline carcinoma,”due to its predominant occurrence in midline organs.4 However,subsequent reports revealed NC’s emergence in numerous nonmidline organs,leading to its reclassification as the independent entity“NUT carcinoma of the thorax”by the WHO in 2015.5 NC exhibits rapid progression and profound resistance to conventional radiotherapy and chemotherapy.展开更多
文摘目的探讨长链非编码RNA(lncRNA)NUTM2B-AS1在口腔鳞状细胞癌组织中的表达及对口腔鳞状细胞癌细胞侵袭和迁移的影响及分子机制。方法采用癌症基因组图谱(The Cancer Genome Atlas,TCGA)数据库分析口腔鳞状细胞癌组织和癌旁组织中NUTM2B-AS1表达水平。qRT-PCR法检测口腔上皮角质细胞HOK、口腔鳞状细胞癌细胞系Cal-27、SCC-25、SCC-9、HSC-3中NUTM2B-AS1表达水平。Cal-27细胞分别转染NUTM2B-AS1过表达载体(pmirGLO-NUTM2B-AS1)和空载体(pmirGLO),记为NUTM2B-AS1组和对照组,qRT-PCR验证每组细胞中NUTM2B-AS1表达水平。Transwell侵袭实验和细胞划痕实验检测Cal-27细胞侵袭和迁移。生物信息学方法和双荧光素酶报告基因实验验证NUTM2B-AS1和miR-770-5p的靶向关系。qRT-PCR检测Cal-27细胞miR-770-5p的表达,Western blot检测Cal-27细胞Sirt7/Smad4信号通路蛋白(Sirt7、E-cadherin、Smad4、MMP-7、Vimentin)的表达。结果与癌旁组织比较,口腔鳞状细胞癌组织中NUTM2B-AS1表达显著降低(P<0.01)。与HOK细胞比较,口腔鳞状细胞癌细胞系Cal-27、SCC-25、SCC-9、HSC-3中NUTM2B-AS1表达显著降低(P<0.01),Cal-27细胞中NUTM2B-AS1表达最低(P<0.01)。与对照组比较,NUTM2B-AS1组Cal-27细胞中NUTM2B-AS1表达显著升高(P<0.01)。与对照组比较,NUTM2B-AS1组Cal-27细胞侵袭数显著降低(P<0.01),Cal-27细胞划痕愈合率显著降低(P<0.01)。miR-770-5p是NUTM2B-AS1的靶向结合基因(P<0.01)。与对照组相比,NUTM2B-AS1组Cal-27细胞中miR-770-5p表达显著降低(P<0.01),Sirt7、E-cadherin蛋白表达显著升高(P<0.01),Smad4、MMP-7、Vimentin蛋白表达下降(P<0.01)。结论NUTM2B-AS1在口腔鳞状细胞癌组织和细胞系中低表达,高表达NUTM2B-AS1可抑制口腔鳞状细胞癌细胞侵袭和迁移,其作用机制与靶向下调miR-770-5p表达有关。
文摘1.INTRODUCTION NUT midline carcinoma family member 1(NUTM1)fusions are primarily known for their association with poorly differen-tiated and aggressive carcinomas,predominantly affecting mid-line structures in children and young adults.Recently,NUTM1 fusions have been identified various malignancies,including hematologic malignancies.1 Among these,NUTM1-rearranged B-cell lymphoblastic leukemia(B-ALL)has emerged as a dis-tinct subtype that typically presents in children and is associated with positive clinical outcomes.
文摘伴睾丸核蛋白(nuclear protein in testis,NUT)基因重排的中线癌又称NUT癌,是一种罕见的高度侵袭性肿瘤,根据NUT中线癌家族成员1(NUT midline carcinoma family member 1,NUTM1)基因发生重排或突变定义。常规治疗方法对NUT癌效果欠佳,绝大多数患者预后差。现阶段对该基因变异的认识不足是制约NUT癌诊治取得进展的主要障碍。目前在临床实践中缺乏针对NUT癌临床特征、诊断及治疗方法的标准化指南,限制了临床医师对该疾病的充分认识。为了给临床医师提供更加明确规范的诊断参考依据,中国抗癌协会肿瘤基因诊断专业委员会中线(NUT)癌基因诊断工作组及中国抗癌协会肿瘤标志专业委员会组织了临床、病理、分子检测和生物信息分析等领域专家,综合国内外NUT癌临床应用的共识指南、重要文献及临床实践经验,共同制定了本共识,对NUT癌临床诊疗给出专家组意见,期望为临床医师提供NUT癌诊疗指导意见,降低NUT癌误诊率,提高治疗效果和预后。
文摘中线癌(nuclear protein in testis carcinoma),又称NUT癌,是一种罕见的高度侵袭性恶性肿瘤,最常见于中线器官和肺。NUT癌的特征性遗传学改变是NUT癌家族成员1(NUT midline carcinoma family member 1,NUTM1)基因重排。本文将对其最常见的融合形式溴结构域蛋白4(bromodomaincontaining protein 4,BRD4)-NUTM1融合基因的致病机制以及靶向药物研发的进展进行综述。
文摘伴睾丸核蛋白(nuclear protein in testis,NUT)基因重排的中线癌是一种由NUTM1(NUT midline carcinoma family member 1)基因重排定义的罕见高侵袭性肿瘤。常规治疗方法对NUT癌效果欠佳,绝大多数患者预后差。《中线(NUT)癌诊断与治疗专家共识(2023版)》于2023年10月发布,以期为临床医师提供更加明确和规范的诊治参考依据,对广大NUT癌患者有着重要意义。本文将对该共识的主要内容进行解读。
基金supported by the China Postdoctoral Science Foundation(grant number 2022M723207)the Medical Scientific Research Foundation of Zhejiang Province,China(grant number 2023KY666)+8 种基金Zhejiang Traditional Chinese Medicine Science Fund Project(grant number 2024ZL372)Qiantang Cross Fund Project(grant number 2023-16)the National Natural Science Foundation of China of Zhejiang Cancer Hospital Cultivation Project(grant number PY2023006)the Medical Scientific Research Foundation of Zhejiang Province,China(grant number 2024KY812)the Natural Science Foundation of Zhejiang Province(grant number Q24H160110)the National Natural Science Foundation of China(grant number NSFC82371851)the Science and Technology Foundation of Guizhou Province(Outstanding Young Scientists of Guizhou Province)(grant number Qiankeherencai-YQK(2023)021)the Science and Technology Foundation of Guizhou Province(grant number Qiankehejichu-ZK(2023)General 212)the Science and Technology Foundation of Guizhou Province(grant number Qiankehechengguo-LC(2025)General 068).
文摘1(NUTM1)gene rearrangements(15q14).In 1991,two independent research teams reported NC cases characterized by the t(15;19)translo-cation.1,2 In vitro studies by French et al.3 led to the pivotal discovery of NC in 2003 as a distinct disease entity driven by the fusion of bromodo-main and extraterminal domain(BET)protein 4(BRD4)and NUTM1.In 2004,the World Health Organization(WHO)classified tumors with t(15;19)translocation as a thymic malignancy and designated it“NUT midline carcinoma,”due to its predominant occurrence in midline organs.4 However,subsequent reports revealed NC’s emergence in numerous nonmidline organs,leading to its reclassification as the independent entity“NUT carcinoma of the thorax”by the WHO in 2015.5 NC exhibits rapid progression and profound resistance to conventional radiotherapy and chemotherapy.
